RxDoctor Payments Data

Karen Albright

Acute Care · San Antonio, TXNPI 1245601467

Payments from drug & device makers

$1,147in general payments, 2019–2025

Across 41 payments — averaging $27.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$317
  • Medtronic$201
  • Si-bone, Inc.$199
  • Abbott$128
  • Biohaven Pharmaceuticals, Inc.$85
  • Vertos Medical, Inc.$71
  • plus $147 from 5 others

What the payments were for

  • Speaking & faculty fees$545%
  • Food & beverage$1,09495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,147 in reported general payments places this provider in the 75th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$212,312
Medicare patients
204
Services billed
4,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant14$25,009
Ajovy SyringeFremanezumab-Vfrm12$8,554
Emgality PenGalcanezumab-Gnlm11$7,030
Gabapentin124$2,423
Tizanidine Hcl62$786
Duloxetine Hcl27$516
RizatriptanRizatriptan Benzoate16$447
Cyclobenzaprine Hcl45$389
Methocarbamol23$360
Baclofen32$299
Ondansetron OdtOndansetron11$261
Methylprednisolone30$237
Topiramate11$106
Ropinirole Hcl12$76
Naproxen11$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$317$25,00914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,323 acute care providers in Texas.

Other acute care in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →